Welcome to our dedicated page for Iovance Biotherp news (Ticker: IOVA), a resource for investors and traders seeking the latest updates and insights on Iovance Biotherp stock.
Iovance Biotherapeutics (IOVA) pioneers tumor-infiltrating lymphocyte (TIL) therapies for advanced cancers, leading the next generation of personalized immunotherapies. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical milestones, regulatory developments, and strategic initiatives.
Access timely announcements including FDA submissions, clinical trial data publications, manufacturing advancements, and partnership agreements. Our curated collection ensures you stay informed about IOVA developments impacting oncology treatment paradigms and biopharmaceutical innovation.
Key updates cover therapy approvals, research collaborations, financial results, and scientific presentations. All content is verified through primary sources to maintain accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to Iovance's latest progress in developing TIL-based therapies for melanoma, cervical cancer, and other solid tumors. Regularly updated to serve as your definitive resource for IOVA-related news analysis.
Iovance Biotherapeutics has announced new clinical data for its TIL therapy, LN-145, showcasing a 21.4% overall response rate in heavily pre-treated patients with metastatic non-small cell lung cancer (mNSCLC). The therapy demonstrated effectiveness even in patients resistant to previous treatments. The clinical trial results were presented during the SITC Annual Meeting in Washington, D.C. and suggest continued investigation of LN-145 in upcoming studies. The company emphasizes the significance of these findings in addressing unmet needs in second-line mNSCLC treatment.
Iovance Biotherapeutics (NASDAQ: IOVA) has announced promising clinical data for its tumor-infiltrating lymphocyte (TIL) therapy, showcasing an overall response rate (ORR) of 50% in cervical cancer patients and 87.5% in metastatic melanoma when combined with pembrolizumab. For relapsed non-small cell lung cancer (NSCLC), the TIL therapy demonstrated an ORR of 21.4%. Iovance will present updated results at the upcoming SITC Annual Meeting, signaling a potentially significant step forward in immunotherapy for various cancers.
Iovance Biotherapeutics (NASDAQ: IOVA), a leader in T cell-based cancer therapies, announced its participation in several major conferences in November 2021. Key presentations include:
- Festival of Biologics, Basel: November 9 at 11:10 a.m. ET
- Cowen 5th Annual IO Next Summit: November 15 at 3:45 p.m. ET
- Stifel 2021 Virtual Healthcare Conference: November 17 at 11:20 a.m. ET
- Cell Immunotherapies for Solid Tumors Summit: November 18 at 10:30 a.m. ET
- Piper Sandler 33rd Annual Virtual Healthcare Conference: November 22 at 10:00 a.m. ET
The company focuses on pioneering tumor infiltrating lymphocyte therapies for cancer treatment.
Iovance Biotherapeutics (NASDAQ: IOVA) reported its third quarter 2021 results, showcasing ongoing advancements in T cell-based cancer immunotherapies. The company continues to develop lifileucel, with an expected FDA BLA submission in H1 2022. Iovance received FDA Fast Track designation for lifileucel in combination with pembrolizumab for metastatic melanoma. The cash position stood at $660.8 million, adequate to fund operations into 2023. However, net loss for Q3 was $86.1 million, up from $58.6 million in Q3 2020, raising concerns about increasing R&D and administrative expenses.
Iovance Biotherapeutics (NASDAQ: IOVA) will announce its Q3 financial results on November 4, 2021, followed by a conference call at 4:30 p.m. ET. The company focuses on T cell-based cancer immunotherapies, with its lead candidate, lifileucel, aimed at treating metastatic melanoma. Iovance's TIL platform shows promise across various solid tumors, with ambitions to lead in tumor-infiltrating lymphocyte therapies.
Iovance Biotherapeutics will host a webcast on November 13, 2021 at 5:30 p.m. ET to present updates on its tumor-infiltrating lymphocyte (TIL) therapies in lung cancer and in combination with pembrolizumab. The conference will include insights from key leaders in the field. Additionally, posters will be presented at the SITC Annual Meeting from November 12-14, 2021, detailing phase 2 data for TIL therapy. Iovance aims to pioneer TIL cell therapies, with the potential first one-time cell therapy for solid tumors.
Iovance Biotherapeutics has announced key clinical data presentations at the SITC 36th Annual Meeting on TIL cell therapies for advanced cancers. An oral presentation on November 13 will focus on phase 2 results of TIL in combination with pembrolizumab for immune checkpoint inhibitor-naïve patients. Additionally, posters will cover TIL monotherapy efficacy in NSCLC and advancements in TIL manufacturing. These developments highlight Iovance's commitment to pioneering cancer immunotherapy.
Iovance Biotherapeutics has announced the successful infusion of the first patient with TIL cell therapy LN-145, produced at the Iovance Cell Therapy Center (iCTC). This milestone is part of the IOV-COM-202 study focusing on metastatic non-small cell lung cancer. The state-of-the-art iCTC facility in Philadelphia aims to meet the demand for TIL therapies, with capacity for thousands of patients. The company plans to balance internal and external TIL manufacturing, prioritizing accessibility and cost reduction for its therapies.
Iovance Biotherapeutics reported its second quarter 2021 financial results, highlighting advances in TIL therapy for cancer. The company has a cash position of $708.7 million as of June 30, sufficient to fund operations through 2023. Key clinical data was presented, showing an 86% overall response rate for lifileucel in combination with pembrolizumab for anti-PD-1 naïve melanoma. However, the net loss for Q2 was $81.4 million, an increase from $63 million in Q2 2020, with R&D expenses rising to $62.1 million.
